Lsd Case Study 1969 Dodge
The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or mescaline.
To evaluate the association between the lifetime use of psychedelics and current mental health in the adult population.
Data drawn from years 2001 to 2004 of the National Survey on Drug Use and Health consisted of 130,152 respondents, randomly selected to be representative of the adult population in the United States. Standardized screening measures for past year mental health included serious psychological distress (K6 scale), mental health treatment (inpatient, outpatient, medication, needed but did not receive), symptoms of eight psychiatric disorders (panic disorder, major depressive episode, mania, social phobia, general anxiety disorder, agoraphobia, posttraumatic stress disorder, and non-affective psychosis), and seven specific symptoms of non-affective psychosis. We calculated weighted odds ratios by multivariate logistic regression controlling for a range of sociodemographic variables, use of illicit drugs, risk taking behavior, and exposure to traumatic events.
21,967 respondents (13.4% weighted) reported lifetime psychedelic use. There were no significant associations between lifetime use of any psychedelics, lifetime use of specific psychedelics (LSD, psilocybin, mescaline, peyote), or past year use of LSD and increased rate of any of the mental health outcomes. Rather, in several cases psychedelic use was associated with lower rate of mental health problems.
We did not find use of psychedelics to be an independent risk factor for mental health problems.
Citation: Krebs TS, Johansen P-Ø (2013) Psychedelics and Mental Health: A Population Study. PLoS ONE 8(8): e63972. https://doi.org/10.1371/journal.pone.0063972
Editor: Lin Lu, Peking University, China
Received: August 19, 2012; Accepted: April 11, 2013; Published: August 19, 2013
Copyright: © 2013 Krebs, Johansen. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Both authors were supported by the Research Council of Norway (grant 185924). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Psychedelic plants have been used for celebratory, religious or healing purposes for thousands of years –. Use of psychedelics increased in the 1960s and has remained widespread in many parts of the world ever since. Over 30 million people living in the US have used lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), and mescaline (peyote and other cacti) . Common reasons for using psychedelics include mystical experiences, curiosity, and introspection . The classical serotonergic psychedelics are not known to cause damage to the brain or other organs of the body, or cause withdrawal symptoms, elicit addiction or compulsive use , or cause birth defects or genetic damage . Psychedelics often elicit deeply personally and spiritually meaningful experiences and sustained beneficial effects –. Psychedelics can often cause period of confusion and emotional turmoil during the immediate drug effects  and infrequently such adverse effects last for a few days after use. Psychedelics are not regarded to elicit violence  and dangerous behavior leading to suicide or accidental death under the influence of psychedelics is regarded as extremely rare . LSD and psilocybin are consistently ranked in expert assessments as causing less harm to both individual users and society than alcohol, tobacco, and most other common recreational drugs –. Given that millions of doses of psychedelics have been consumed every year for over 40 years, well-documented case reports of long-term mental health problems following use of these substances are rare. Controlled studies have not suggested that use of psychedelics lead to long-term mental health problems , , , . Here we evaluate the association between the use of psychedelics and mental health among US adults.
Materials and Methods
This study was exempt from review by our Regional Committee for Medical Research Ethics because all data are available in the public domain without any identification of personal information. The National Survey on Drug Use and Health (NSDUH) was approved by an institutional review board of the Research Triangle Institute.
Source, Population and Data
The annual NSDUH survey provides estimates of substance use and mental health indicators from a randomly-selected sample representative of the general US civilian non-institutionalized adult population. The Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services is responsible for the NSDUH study design and methods of assessment. Trained interviewers met the randomly-selected participants in their homes, and participants listened to recorded questions via headphones and then entered their answers directly into a computer, providing a highly confidential and standardized setting. We pooled data from NSDUH survey years 2001 to 2004 because in these years participants were asked about symptoms of a range of psychiatric disorders and about whether they have been exposed to an extremely stressful event. We excluded half of the participants from year 2004 because of changes in the survey questions. We restricted the samples to adults aged 18 years and older because younger participants were asked different mental health questions than adults. The response rate was 78%. In addition, approximately 10% of participants were excluded from the public use data file, either because of excessive missing data on drug use or because they were excluded at random in order to increase anonymity. Detailed information on the sampling and data collection methods, including interview instructions and questionnaires, confidentiality and informed consent are available at the NSDUH website (http://oas.samhsa.gov/nsduh.htm).
Use of Psychedelics
We counted participants as having any lifetime psychedelic use if they affirmed use of LSD, psilocybin, mescaline, or peyote. We also examined use of each of the substances separately. Mescaline and peyote was combined into one category “mescaline/peyote” because mescaline is the active substance in peyote cactus, but peyote was also examined separately. Information was also available on past year use of LSD, but not past year use of psilocybin or mescaline. LSD, psilocybin, and mescaline are all classical serotonergic psychedelics with main mechanism of action at the serotonin 2A receptor , .
Mental Health Indicators
Serious psychological distress.
The K6 scale provides a valid assessment of general psychological distress during the worst month of the past year, that are common to a broad range of psychiatric disorders, with strong accuracy in discriminating between people with and without one or more diagnoses from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV ) . The K6 scale asks about frequency, using a 0 to 4 category scale, of six symptoms of psychological distress: feeling nervous, feeling hopeless, feeling restless or fidgety, feeling so sad or depressed that nothing could cheer you up, feeling everything was an effort, and feeling no good or worthless. A score of 13 or more on the K6 scale is the validated and recommended cut-point for serious psychological distress .
Mental health treatment.
Past year mental health treatment was divided into four outcome variables: inpatient mental health treatment, outpatient mental health treatment, psychiatric medication prescription, and felt a need but did not receive mental health treatment. Inpatient mental health treatment included overnight stays for alcohol or drug problems at hospitals or rehabilitation centers. Outpatient mental health treatment included treatment for alcohol or drug problems at rehabilitation centers, mental health centers, emergency rooms, doctors’ offices, prisons or jails, or self-help groups. Data was not available on medication prescription for alcohol or drug problems. Needed but did not receive mental health treatment included respondents who felt that they needed treatment for alcohol or drug problems but did not receive any such treatment.
Psychiatric symptom indicators.
Symptoms indicators for eight DSM-IV psychiatric disorders were evaluated using the short form of the World Health Organization Composite International Diagnostic Interview (CIDI-SF) . The CIDI-SF consists of between three to eight questions per disorder and covers eight disorders: panic disorder, major depressive episode, mania, social phobia, general anxiety disorder, agoraphobia, posttraumatic stress disorder, and non-affective psychosis. We also examined each of the seven symptoms of non-affective psychosis individually (the cut-off for non-affective psychosis was two or more of the seven symptoms). The CIDI-SF appears to overestimate the rate of diagnoses, but most false-positive cases have some degree of the disorder even if they fail to meet full diagnostic criteria , . We used the CIDI-SF to compare groups on symptom indicators, not to estimate prevalence of psychiatric diagnoses. We used standard scoring and cut-off points .
We selected control variables based on associations with mental health in previous research . Control variables consisted of a variety of sociodemographic, psychological, and drug use variables: age at interview (11 categories), gender, race/ethnicity (7 categories: non-Hispanic white, non-Hispanic black, non-Hispanic Native American, non-Hispanic Native Hawaiian or Pacific Islander, non-Hispanic Asian, non-Hispanic more than one race, Hispanic), education (4 categories: did not graduate high school; high school graduate; some college; college graduate), household income (4 categories: less than $20,000; $20,000 to $49,999; $50,000 to $74,999; $75,000 or more), marital status (2 categories: single; married), likes to test self with risky behavior (“How often do you like to test yourself by doing something a little risky?”; 4 categories: never, seldom, sometimes, always), lifetime exposure to an extremely stressful event (“Such as being in combat, being involved in a life-threatening accident, being involved in a disaster, being physically beaten or sexually abused, or any other event which was extremely upsetting or stressful”), and lifetime non-medical use of each of ten types of drugs: cannabis (marijuana), opiates (heroin, opiate pain relievers), cocaine, tranquilizers/sedatives (benzodiazepines, barbiturates), stimulants (amphetamine, methamphetamine, methylphenidate), MDMA (ecstasy), inhaled anesthetics (nitrous oxide, ether), alkyl nitrites (poppers), other inhalants (solvents, volatile chemicals), and PCP (phencyclidine). Additionally, in the analyses of past year use of LSD we also included as control variables past year use of the other drugs listed above, but with only one variable for any past year inhalant use because data on specific inhalants was not available.
We used multivariate logistic regression to calculate associations between the past year mental health indicators and use of psychedelics, including lifetime use of any psychedelics, lifetime use of LSD, psilocybin, mescaline/peyote, or peyote, and past year use of LSD. We also calculated the associations between the past year mental health indicators and lifetime use of any psychedelics in the presence or absence of other risk factors in stratified subgroups (sex, age, past year illicit drug use, lifetime exposure to an extremely stressful event). Participants with missing data on relevant mental health outcomes or past year illicit drug use were excluded.
The estimated associations between the use of psychedelics are presented as adjusted odds ratios (aOR), 95% confidence intervals (CI), and p-values. A statistically significant odds ratio greater than one indicates an association, and an odds ratio less than one indicates an inverse association. Because the mental health outcomes are all relatively uncommon, in this case, the odds ratio is a close approximation to the relative risk. For example, an adjusted odds ratio of 0.6 for a given outcome indicates that the rate of that outcome in psychedelic users is approximately 60% the rate in non-psychedelic users, after adjusting for control variables.
We used a standard alpha of 0.05; however any significant results should be considered in the context of the number of statistical analysis performed. It is typically recommended to have at least 10 events per predictor variable for multivariate logistic regression, although recent simulation studies suggest as few as 5 events per predictor variable is sufficient . All the unstratified analyses had at least 10 events per predictor variable, with 21 to 379 events per predictor variable for mental health indicators besides the specific psychotic symptoms. In the stratified analyses of three of the more uncommon specific psychotic symptoms (“force inserting thoughts”, “force stealing thoughts”, “plot to harm you”) there were in some cases less than 10 and as few as 5 events per predictor variable. For all control variables the variance inflation factors were under 2.5, indicating little multi-collinearity. All calculations took into account the weighting variables and complex sample design variables of the NSDUH. For all calculations we used SPSS/PASW Statistics (version 18.0.3) with the Complex Samples Module.
Characteristics of Psychedelic Users
The sample consisted of 130,152 respondents, of which 21,979 (13.4% weighted) reported lifetime use of any psychedelic. Tables 1 and 2 show the characteristics of the participants, according to lifetime use of any psychedelic. Compared to respondents with no lifetime use of any psychedelic, respondents with lifetime use of any psychedelic were more likely to be younger, male, white, Native American, or more than one race, have somewhat higher income and more education, not be married, like to test self by doing risky things, experienced an extremely stressful event, and to have used all classes of illicit drugs. For all the control variables, the differences between psychedelic users and non-users was statistically significant (Chi-square tests, for all p<0.001). Before adjusting for these confounding factors, psychedelic users had higher rates of all indicators of mental health problems.
Logistic Regression Results
Tables 3 and 4 show the results of the multivariate logistic regression analyzes.
Serious psychological distress.
Lifetime psychedelic use was not significantly associated with serious psychological distress in the worst month of the past year. Among the specific psychedelics, lifetime psilocybin use (aOR 0.8, p = 0.009), lifetime mescaline use (aOR 0.9, p = 0.04), and past year LSD use (aOR 0.7, p = 0.01) were associated with lower rates of serious psychological distress.
Mental health treatment.
Lifetime psychedelic use was not significantly associated with any of the mental health treatment variables. Among the specific psychedelics there were a number of significant associations with lower rate of receiving or needing mental health treatment. Lifetime LSD use was significantly associated with a lower rate of outpatient mental health treatment (aOR 0.9, p = 0.002) and psychiatric medication prescription (aOR 0.9, p = 0.04). Lifetime psilocybin use was significantly associated with a lower rate of inpatient mental health treatment (aOR 0.8, p = 0.04) and psychiatric medication prescription (aOR 0.8, p = 0.00008). Lifetime mescaline/peyote use was significantly associated with a lower rate of psychiatric medication prescription (aOR 0.8, p = 0.004) and needed but did not receive mental health treatment (aOR 0.8, p = 0.001). Lifetime peyote use was significantly associated with a lower rate of psychiatric medication prescription (aOR 0.8, p = 0.01).
Psychiatric symptom indicators.
Lifetime psychedelic use was not significantly associated with any of the eight past year psychiatric symptom indicators (aOR range 0.8 to 1.1), and lifetime psychedelic use was significantly associated with a lower rate of one of the seven psychotic symptoms (“Felt a force taking over your mind”: aOR 0.7, p = 0.03). Among the specific psychedelics, lifetime psilocybin use was significantly associated with a lower rate of symptoms of panic attacks (aOR 0.9, p = 0.006), and lifetime mescaline/peyote use was significantly associated with a lower rate of symptoms of agoraphobia (aOR 0.6, p = 0.005). Lifetime psilocybin use and lifetime mescaline/peyote use was significantly associated with a lower rate of one of the specific psychotic symptoms (“Felt a force taking over your mind”: psilocybin, aOR 0.6, p = 0.004; mescaline/peyote: aOR 0.7, p = 0.04).
In a series of multivariate logistic regression analyzes stratified by gender (male; female), age (18 to 25 years; 26 and older), any past year illicit drug use (no; yes), or lifetime extremely stressful event ever (no; yes) there were no significant associations with lifetime psychedelic use and greater risk of any of the mental health outcomes. Rather, in twelve cases there was an association with psychedelic use and lower rate of various mental health outcomes; however, most of these cases had marginal statistical significance (0.05<p<0.01). Among females, psychedelic users had a lower rate of the psychotic symptom “felt force taking over mind” (aOR 0.5, 95% CI 0.3 to 0.7, p = 0.0005). Among younger people, psychedelic users had a lower rate of symptoms of generalized anxiety disorder (aOR 0.8, 95% CI 0.6 to 1.0, p = 0.03). Among older people, psychedelic users had a lower rate of psychiatric medications (aOR 0.9, 95% CI 0.8 to 1.0, p = 0.03) and the psychotic symptom “felt force taking over mind” (aOR 0.5, 95% CI 0.3 to 0.8, p = 0.01). Among people with past year illicit drug use, psychedelic users had a lower rate of inpatient mental health treatment (aOR 0.7, 95% CI 0.5 to 0.9, p = 0.02), needed mental health treatment (aOR 0.9, 95% CI 0.7 to 1.0, p = 0.04), symptoms of generalized anxiety disorder (aOR 0.7, 95% CI 0.5 to 1.0, p = 0.05), symptoms of agoraphobia (aOR 0.6, 95% CI 0.4 to 1.0, p = 0.05), and symptoms of posttraumatic stress disorder (aOR 0.7, 95% CI 0.5 to 1.0, p = 0.02). Among people without a lifetime extremely stressful event, psychedelic users had a lower rate of symptoms of psychosis (aOR 0.5, 95% CI 0.3 to 0.9, p = 0.03) and the psychotic symptoms “felt force inserting thoughts” (aOR 0.4, 95% CI 0.2 to 0.9, p = 0.02) and “felt force steal thoughts” (aOR 0.3, 95% CI 0.1 to 0.7, p = 0.008).
Native Americans reported a high rate of lifetime psychedelic use (25%, weighted), with a high rate of lifetime peyote use (14%, weighted). However, less than 1% of lifetime psychedelic users and less than 3% of lifetime peyote users were Native Americans. Many Native Americans use peyote within legally-protected religious practice . Excluding Native Americans changed the adjusted odds ratios on average less than 2%, and mescaline/peyote use was no longer statistically significantly associated with lower rate of the specific psychotic symptom “felt a force taking over your mind” (aOR = 0.7, p = 0.06).
On each analysis, less than 2% of participants were missing data. Including participants with missing data by setting missing data to “no” or “0” had a minimal effect on the results (less than 4% change in adjusted odds ratios, on average) and had no effect on statistical significance.
Lack of Associations with Mental Health Problems
We found no relation between lifetime use of psychedelics and any undesirable past year mental health outcomes, including serious psychological distress, mental health treatment (inpatient, outpatient, medication, felt a need but did not receive), or symptoms of panic disorder, major depressive episode, mania, social phobia, generalized anxiety disorder, agoraphobia, posttraumatic stress disorder, or non-affective psychosis. In addition to not being significantly different from no association, in all cases the calculated adjusted odds ratios (aOR) were small (for all, psychedelic use aOR ≤1.2). Stratifying by age, gender, past year illicit drug use, or lifetime extremely stressful event did not substantially change the results of any of the logistic regression analyses. Likewise, lifetime use of LSD, psilocybin, mescaline, or peyote, or past year use of LSD, was not associated with a higher rate of mental health problems. There were a number of weak associations between use of any psychedelic or use of specific psychedelics and lower rate of mental health problems; these results might reflect beneficial effects of psychedelic use, relatively better initial mental health among people who use psychedelics, or chance “false positive” findings. Our results are consistent with assessments of the harm potential of psychedelics ,  and with information provided by UN, EU, US, and UK official drug education programs , –, insofar as these sources do not conclude that psychedelics are demonstrated to cause lasting anxiety, depression, or psychosis.
This study had a retrospective, cross-sectional design, making it impossible to draw causal inferences. Many potentially important risk factors, such as family mental health history, were not available. Longitudinal data were not available on mental health or other factors before psychedelic use. We cannot exclude the possibility that use of psychedelics might have a negative effect on mental health for some individuals or groups, perhaps counterbalanced at a population level by a positive effect on mental health in others. We did not adjust for multiple comparisons, so some of the associations with weak statistical significance are likely due to chance. Screening questions, rather than diagnostic interviews, were used as symptom indicators. Self-reports of drug use behaviors and mental health questions could be influenced by memory errors and under-reporting; however, a 14-year longitudinal study reported good consistency over time in reporting of LSD use . Dosage and purity of street drugs is often unknown, and in particular substances sold as mescaline often contain LSD or other substances . A small group (<2%) of US adults in prison, hospital, or military service were not included in the NSDUH sampling. We did not examine active drug or short-term effects.
Clinical Studies in Healthy Volunteers
The lack of association between the use of psychedelics and indicators of mental health problems in this large population survey is consistent with clinical studies in which LSD or other psychedelics have been administered to healthy volunteers . Eight recent double-blind, placebo-controlled studies of psilocybin in healthy volunteers, with follow-up between 8 and 16 months, reported “no subsequent drug abuse, persisting perception disorders, prolonged psychosis or other long term impairment of functioning” . And two other recent clinical trials of psilocybin in 54 healthy volunteers found no evidence of lasting adverse effects , .
Cross-sectional and Case-control Studies
A case-control study of Native Americans failed to find any evidence of cognitive or mental health deficits among people who regularly used peyote in religious services compared to those who did not use peyote, rather total lifetime peyote use (mean 300 occasions, range 150–500) was associated with overall better mental health . Likewise, a longitudinal case-control study found that people who had each used the shamanic beverage ayahuasca, containing the psychedelic dimethyltryptamine (DMT) which is chemically similar to psilocybin, in over 360 religious ceremonies scored significantly lower on all psychopathology measures compared to people who regularly participated in non-psychedelic religious groups, both at baseline and at one year follow-up . A population study reported that any lifetime use of cocaine and/or psychedelics was associated with prior lifetime history of two or more of 15 psychotic symptoms, but not one psychotic symptom ; in this study cocaine and amphetamine use were not included as control variables in the analyzes of psychedelic use, although both cocaine and amphetamine use were reported to be associated with psychotic symptoms; although the data came from a 10-year longitudinal study, data were aggregated over all time periods and no distinction was made between psychotic symptoms occurring before or after onset of psychedelic use. Another retrospective population study did not find an association between any lifetime “psychedelic” use and panic attacks or depression, but did report an association between dependence on “psychedelics” and panic attacks ; however, in this study the number of events was small, and the dissociative anesthetic PCP was included as a psychedelic, even though it is well known that PCP has quite different subjective effects, dependence potential, and neurobiological mechanisms than the serotonergic psychedelics. A follow-up of 29 patients with first-break psychosis attributed to LSD use found that these individuals were “essentially similar” to first-break psychosis patients with no LSD use in terms of premorbid adjustment, course of illness, and family history of inpatient treatment, and course of illness  (see also ).
“Flashbacks” and Perceptual Phenomena
In this study, lifetime use of psychedelics and past year use of LSD was not associated with past year symptoms of visual phenomena (“seeing something others could not”), panic attacks, psychosis, or overall serious psychological distress. Thus, our findings does not support either the idea of “flashbacks” described in extreme cases as recurrent psychotic episodes, hallucinations, or panic attacks, or the more recent “hallucinogen persisting perceptual disorder” (HPPD) described as persistent visual phenomena with accompanying anxiety and distress. All of the purported symptoms of HPPD are also present in people who have never used psychedelics , . Occasional visual phenomena are common in the general population , , especially among people with anxiety disorders . Recent randomized controlled trials with psilocybin do not report any cases of “flashbacks” or persistent visual phenomena , , . Interviews with over 500 regular participants in Native American peyote ceremonies did not identify anyone with “flashbacks” or persistent visual symptoms . Interviews with 120 adults in the US complaining of persistent visual symptoms found that only 5% had ever used LSD (in comparison, over 10% of the general US adult population has used LSD ) and there did not seem to be any relationship between drug use and visual symptoms . Only two small studies have reported higher rates of visual symptoms in LSD users compared to non-users , . Both studies had serious methodological problems: participants in both studies were psychiatric inpatients who knew that the purpose of the studies was to document harms from LSD; the LSD group and the control groups were not matched on other drug use or psychiatric diagnosis; and in the first study several of the people included in the LSD group were later found to have epilepsy, panic, anxiety, affective disorder, or temporoparietal abnormalities that may be related to visual symptoms . In case reports of “flashbacks” or HPPD, symptom onset is often weeks, even years, after last psychedelic use, and a causal relationship between persistent perceptual symptoms and use of psychedelics remains unproven. Overall, the validity of the HPPD diagnosis remains scant. HPPD appears to fit within the somatic symptom disorders . In an illustrative case example, a young man was diagnosed with HPPD by the originator of the diagnosis; symptoms began in conjunction with major life changes and several weeks after taking LSD; on initial consultation with physicians, he was told that his vision was fine and somatization disorder was implied; he improved after psychotherapy for his depression and worries, and reassurance that his visual experiences were ordinary perceptual phenomena that most people ignore .
Comments on Case Reports
Case reports of long-term psychiatric problems attributed to LSD, include psychosis, panic attacks, other anxiety disorders, and depression , . There are very few case reports of prolonged psychiatric symptoms following psilocybin or mescaline , . Almost all claims of psychiatric harm caused by peyote have been found on examination of medical records to be due to pre-existing schizophrenia or other causes , . Several issues are important to keep in mind when considering case reports , . 1) Adverse effects of psychedelics are usually short-lived; serious psychiatric symptoms following psychedelic are typically resolved within 24 hours or at least within a few days. 2) Both mental illness and psychedelic use are prevalent in the population, likely leading to many chance associations; for instance, about 3% of the general public will have a psychotic disorder sometime in their lives . 3) The typical onset period of both mental illness and psychedelic use occurs in late adolescence and early adulthood, again possibly leading to mistaken causal inferences. 4) Most case reports do not rule-out preexisting psychiatric difficulties, life stresses, or use of other drugs. Many psychiatric disorders are believed to be heavily influenced by genetics and earlier experiences, even if symptoms are often first triggered by a stressful event. Note, however, that people with first-episode psychosis often have no apparent family or personal history of mental illness, whether or not if they have previously used psychedelics . 5) Because of the striking subjective effects of psychedelics, some people attribute psychiatric symptoms to the use of psychedelics even if the symptoms started months or years later. 6) Some health professionals may have a biased view since they meet people with mental health problems and have little or no contact with the majority of psychedelic users. 7) Caution should be used when generalizing from LSD to other psychedelics because of emerging evidence of unique effects of LSD . 8) Case reports of mental health problems following psychedelics are often comparable to case reports of mental health problems linked to intensive meditation –, visiting holy sites , , or viewing beautiful artwork and sublime natural scenes .
The Substance Abuse and Mental Health Data Archive provided the data files from the National Survey on Drug Use and Health, which was sponsored by the Office of Applied Studies of the Substance Abuse and Mental Health Services Administration.
Conceived and designed the experiments: TSK PØJ. Analyzed the data: TSK. Wrote the paper: PØJ TSK.
- 1. McGlothlin WH (1964) Hallucinogenic Drugs: A Perspective with Special Reference to Peyote and Cannabis. RAND Corp. Available: http://www.rand.org/pubs/papers/P2937.html. Accessed 2013 Apr 30.
- 2. Bruhn JG, De Smet PA, El-Seedi HR, Beck O (2002) Mescaline use for 5700 years. Lancet 359: 1866.
- 3. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101: 131–181.
- 4. Krebs TS, Johansen PØ (2013) Over 30 million psychedelic users in the United States. F1000 Research (in press).
- 5. Hallock RM, Dean A, Knecht ZA, Spencer J, Taverna EC (2012) A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. Drug Alcohol Depend. 2012 Dec 19 [Epub ahead of print]. pii: S0376-8716(12)00451-6. doi:10.1016/j.drugalcdep.2012.11.010.
- 6. Briggs G, Freeman RK, Sumner JY (2011) Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 9th ed. Lippincott Williams & Wilkins.
- 7. McGlothlin WH, Arnold DO (1971) LSD revisited. A ten-year follow-up of medical LSD use. Arch Gen Psychiatry 24: 35–49.
- 8. Griffiths R, Richards W, Johnson M, McCann U, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22: 621–632.
- 9. Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, et al. (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 218: 649–665.
- 10. Morgan CJA, Muetzelfeldt L, Muetzelfeldt M, Nutt DJ, Curran HV (2010) Harms associated with psychoactive substances: findings of the UK National Drug Survey. J Psychopharmacol 24: 147–153.
- 11. Carhart-Harris RL, Nutt DJ (2010) User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. J Subst Abuse 15: 283–300.
- 12. Doblin R (1991) Pahnke’s “Good Friday Experiment”: a long-term follow-up and methodological critique. J Transpersonal Psy 23: 1–25.
- 13. McWilliams SA, Tuttle RJ (1973) Long-term psychological effects of LSD. Psychol Bull 79: 341–351.
- 14. Hoaken PNS, Stewart SH (2003) Drugs of abuse and the elicitation of human aggressive behavior. Addict Behav 28: 1533–1554.
- 15. European Monitoring Centre for Drugs and Drug Addiction (2011) Drug Profiles: Lysergide (LSD). Available: http://www.emcdda.europa.eu/publications/drug-profiles/lsd. Accessed 2013 Apr 30.
- 16. Nutt D, King LA, Saulsbury W, Blakemore C (2007) Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369: 1047–1053.
- 17. Nutt DJ, King LA, Phillips LD (2010) Drug harms in the UK: a multicriteria decision analysis. Lancet 376: 1558–65.
- 18. Van Amsterdam J, Opperhuizen A, Koeter M, Van den Brink W (2010) Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res 16: 202–207.
- 19. Taylor M, Mackay K, Murphy J, McIntosh A, McIntosh C, et al. (2012) Quantifying the RR of harm to self and others from substance misuse: results from a survey of clinical experts across Scotland. BMJ Open 2: e000774.
- 20. Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25: 1434–1452.
- 21. González-Maeso J, Weisstaub N, Zhou M, Chan P, Ivic L, et al. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53: 439–452.
- 22. American Psychiatric Association (1994) Diagnostic and statistical manual of mental health disorders. 4th ed. Washington DC: American Psychiatric Association.
- 23. Kessler RC, Barker PR, Colpe LJ, Epstein JF, Gfroerer JC, et al. (2003) Screening for serious mental illness in the general population. Arch Gen Psychiatry 60: 184–189.
- 24. Sunderland M, Andrews G, Slade T, Peters L (2011) Measuring the level of diagnostic concordance and discordance between modules of the CIDI-Short Form and the CIDI-Auto 2.1. Soc Psychiatry Psychiatr Epidemiol 46: 775–785.
- 25. International Consortium in Psychiatric Epidemiology (2005) Appendix for “New Scales to Screen for Serious Mental Illness in the General Population”. Available: http://www.hcp.med.harvard.edu/icpe/smi_appendix.php. Accessed 2013 Apr 30.
- 26. Patel V, Lund C, Hatherill S, Plagerson S, Corrigall J, et al.. (2010) Mental disorders: equity and social determinants. In: Blas E, Sivasankara Kurup A, editors. Equity, social determinants and public health programmes. World Health Organization. pp.115–134.
- 27. Vittinghoff E, McCulloch CE (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165: 710–718.
- 28. Catts VS, Catts SV (2010) Psychotomimetic effects of PCP, LSD, and Ecstasy: pharmacological models of schizophrenia? In: Sachdev PS, Keshavan MS, editors. Secondary Schizophrenia. Cambridge University Press. pp.141–168.
- 29. Van Amsterdam J, Opperhuizen A, Van den Brink W (2011) Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol 59: 423–429.
- 30. European Monitoring Centre for Drugs and Drug Addiction (2011) Drug Profiles: Hallucinogenic Mushrooms. Available: http://www.emcdda.europa.eu/publications/drug-profiles/mushrooms. Accessed 2013 Apr 30.
- 31. National Institute on Drug Abuse (2009) DrugFacts: Hallucinogens - LSD, Peyote, Psilocybin, and PCP. Available: http://www.drugabuse.gov/publications/drugfacts/hallucinogens-lsd-peyote-psilocybin-pcp. Accessed 2013 Apr 30.
- 32. United Nations Office on Drugs and Crime (2012) Get the Facts: Hallucinogens. Available: http://www.unodc.org/drugs/en/get-the-facts/hallucinogens.html. Accessed 2013 Apr 30.
- 33. Department of Health and the Home Office (2012) LSD. FRANK Drug Awareness Campaign. Available: http://www.talktofrank.com/drug/LSD. Accessed 2013 Apr 30.
- 34. Department of Health and the Home Office (2012) Magic Mushrooms. FRANK Drug Awareness Campaign. Available: http://www.talktofrank.com/drug/magic-mushrooms. Accessed 2013 Apr 30.
In 1969, the Lockheed Aircraft Corporation created a series of short and presumably unintentionally hilarious anti-drug propaganda films, which we think were meant for junior high age kids to watch but we have to imagine they might also have been screened for the hundreds of thousands of Lockheed’s employees too, as a way of warning them what could happen if they were tempted to experiment with hard drugs… while working on the company’s bombs and planes.
At the time, Lockheed were one of the country’s largest defense contractors, and significant part of our military industrial complex — and if you’ve read the terrific book Acid Dreams: The Complete Social History of LSD: The CIA, the Sixties, and Beyond (originally released as Acid Dreams: The CIA, LSD, and the Sixties Rebellion), then you already know that this was the same military industrial complex — and that would also include the CIA — that decades earlier had given LSD to civilians and military personnel in numerous test environments to see if acid had a possible future use as a mind control tool that could be used during wartime interrogations.
The scripts for these Lockheed-sponsored short films focused on four distinct drug categories — LSD, heroin, amphetamines and barbiturates — and the “studies” were reportedly based on the individual true testimony of drug users who had apparently really bad experiences (really bad) which makes the films even more awesomely hilarious.
Everyone’s favorite in the series (ours too) seems to be “Case Study: LSD,” where we start off at a pretty bitchen late 60s party, with candles and pretty Spanish guitar riffage easing us into all the psychedelic grooviness.
We see a hippie chick with big blonde hair, and in her voiceover narration, she begins telling us “I first dropped acid when I was eighteen…,” which we happen to think is a great way to kick off a conversation at a bitchen late 60s party. You have our attention, girl, tell us what happened next!
She tells us that she’d already read about acid in the newspapers and she’d heard a few friends talk about it, and so she was curious about it too, naturally, and then when she’s offered acid at the party by a guy she’d gone to school with she figures, what the hell, why not?
She then tells us she was already “pretty jacked up on marijuana,” so she drops acid with the dude, who is named Terry (who kinda looks like Elton John to us), and she waits…
“Jacked up on marijuana”
But… nothing happens -- “I don’t know what I was waiting for, a flash or a rush, or whatever…” -- and then, even though she’s apparently “over at these people’s house one night,” she tells us she gets tired of waiting and waiting, and so she goes to the dresser (wait, this party is taking place in someone else’s place, right?), and she puts on “a pair of pink Capri pants and a brown and green blouse.” Right away we’re thinking she’s gotta already be pretty high on some kinda drugs, with that outlandish color combo. (“I thought the colors were beautiful,” she says).
She and the LSD dude Terry decide to split and “trip down” to San Francisco’s Market Street to get a hot dog, placing her order at a fast food window. Then tells us she likes her hot dogs fully loaded with “mustard, and ketchup, and relish, and the usual,” and everything’s lookin’ pretty good until she goes in close for a bite.
That’s when she tells us “somebody started screaming.”
That’s also when the acid kicks in for us too, apparently, as suddenly the screen goes all liquidy — it looks like a combination of squirty mustard, ketchup and relish (you know, “the usual”). Big Blonde Hair looks down and sees that the hot dog has actually turned into a screaming face — it looks to us like a terrifying Sixties-era troll doll’s face, with ketchup hair, and then the hot dog starts telling her that she can’t eat him, he has “a wife and seven kids at home to support.”
BBH turns to Terry/Elton — he’s wearing pretty cool lookin’ beads and what appears to be a nice Nehru shirt, by the way — and they both end up having a conversation with the hard-working family man hot dog, but then she and Terry (she tells us he’s now “on the same trip I was on”) and she realizes she’s probably just hallucinating.
So she goes in to take a bite, and that’s when she tells us the hot dog family man “screamed so loud you could hear it all over town.” She tells us she “had to throw it on the ground,” and she begins stomping on hot dog man with her nice white Keds, telling us “There I was, stomping up and down on this hot dog in the middle of Market Street.”
The screams continue and then she says “I realize I had murdered it, and I took off screaming down the street, scared.”
Around the same time “LSD: A Case Study” was being released by Lockheed, acid was in the news as an increasing national issue among the younger generation, appearing on the cover of Time Magazine, published on September 26, 1969, with the words “Drugs and the Young” prominently displayed along with the image of a dude who looks like someone has squirted ketchup and mustard on his head and then stomped on it.
Inside, in Time‘s feature cover story — titled “Pop Drugs: The High as a Way of Life” — the writers provided their readers varying statistics about youth drug use at the time, pointing out, for example, that at the August 1969 Woodstock music festival in upstate New York, “some 90% of the 400,000 participants openly smoked marijuana [bringing] the youthful drug culture to a new apogee.”
“Rock musicians use drugs frequently and openly,”Time informed us, “and their compositions are riddled with references to drugs, from the Beatles’ ‘I get high with a little help from my friends’ to the Jefferson Airplane’s ‘White Rabbit’ (‘Remember what the dormouse said: Feed your head’)….”
At this same time, on September 21, 1969, President Richard Nixon’s administration had begun a surprise anti-drug measure, called Operation Intercept, which was aimed at disrupting the flow of Mexican marijuana coming into the U.S., resulting in the near-shutdown of border crossings between Mexico and the U.S.. Every car began to be inspected until the inspections were abandoned after weeks of complaints from Mexican officials and travelers. Nixon declared that Operation Intercept had achieved its objective anyway.
(You’ll note here that Lockheed didn’t make a “case study” on marijuana, but if they had, we’re sure it would have been awesome — in 1968, Sonny Bono appeared in this anti-marijuana film).
Perhaps the government felt it needed to step in and encourage Lockheed to make these films, considering that they’d been propping up Lockheed Aircraft Corporation at the time, as the company was struggling financially to stay afloat at the end of 1969.
Lockheed — the nation’s primary producer of the Poseidon and Polaris missiles and they were also involved in the Apollo program too (earlier that year, 530 million TV viewers had watched Neil Armstrong and Buzz Aldrin walk on the moon) — was apparently rife with inefficiency and mismanagement by the end of the Sixties, and near bankruptcy.
This was happening despite the fact that Lockheed had just been awarded a $1.9 billion dollar contract just a few years earlier, when the U.S. Air Force placed an order for a fleet of twenty C-5A military cargo transport jets (this happened over the complaints of the Pentagon, who had suggested the Air Force purchase 747 planes from Boeing instead, but who ever listens to the Pentagon anyway, right?).
Lockheed ended up borrowing $400 million from a consortium of banks in 1969, even they would still end up declaring multimillion dollar losses for the company for ’69 and 1970. It wasn’t enough money, however, and so the failing aerospace giant once again turned to our federal government, who then granted them a $250 million dollar loan guarantee, which Nixon’s administration actually proposed and Congress narrowly ended up passing in August 1971, passing that sizable debt on to the U.S. taxpayer by showing that Lockheed — just like the banks — was simply too big to fail.
Lockheed would survive and grow in the 1970s, of course, ultimately buying another defense contractor, Martin Marietta, and becoming the mega-huge Lockheed Martin, the world’s biggest defense contractor, which was later described by Jonathan Vankin in The Big Book of Scandal as “a company that sold billions of dollars in weapons every year, while covertly functioning as one of the world’s largest organized crime syndicates.”
Hmm… we also think the government should have encouraged Lockheed to make short films about the hazards of dropping bombs instead of dropping acid, but maybe that’s just us.
Anyway, these short films are so great, and we’re glad they were all made, so pass the ketchup, we’re going to finish up a conversation we’re having with this little troll dude we’ve been talking to.